Abstract: A method according to the present disclosure improves sleep states, maintains a sound sleep, restores the balance of gut microbiota disrupted by sleep disorders, and supports the management of health including metabolic syndrome. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Limosilactobacillus reuteri LM1063 strain was deposited with the international depositary authority: the Korean Collection for Type Cultures on Mar. 23, 2017, under the Accession Number: KCTC 13232BP.

Abstract: A composition comprising a decellularized uterine tissue-derived extracellular matrix and a use thereof and, more specifically, a hydrogel composition for three-dimensional culturing an endometrial organoid, a preparation method therefor, and a use thereof are described. The hydrogel composition comprising a decellularized uterine tissue-derived extracellular matrix can be utilized to fabricate an endometrial organoid highly similar to in vivo uterine tissues and organs through the properties, components, and physical properties of the decellularized uterine tissue-derived extracellular matrix, and such endometrial organoids can be advantageously used for in-vivo implantation and in drug tests for various uterus-related diseases.

Abstract: A focused ultrasound apparatus for women is disclosed. According to one aspect of the present disclosure, the focused ultrasound apparatus for women is provided, including a handpiece, a cartridge which is detachably coupled to the handpiece and one side of the cartridge may be inserted into recipient's vagina, an ultrasound generation unit which is equipped on one side of the cartridge and generates a focused ultrasound, a rotation drive unit which rotates the cartridge which is equipped in and coupled to the handpiece around a longitudinal axis of the cartridge, a control unit which controls operations of the ultrasound generation unit and the rotation drive unit, and a procedure assistance unit which is movably coupled to the cartridge in order to enable an adjustment of an insertion depth of the cartridge inserted into a recipient's vagina.

Abstract: A solid dispersion of amorphous efinaconazole and a method for preparing the same are proposed. The solid dispersion includes an amorphous form of efinaconazole and at least one stabilization carrier selected from hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), ethyl cellulose (EC), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), polyvinylpyrrolidone (PVP), polyacrylic acid (PAA), saccharin, and malonic acid. The solid dispersion undergoes minimal thermodynamic deformation when exposed to ambient temperature and humidity, achieving improved stability, while maintaining the inherent improved stability and bioavailability of amorphous efinaconazole.

Abstract: The present invention relates to a novel method for preparing efinaconazole using an ionic liquid as a medium. The method includes subjecting 1-[[(2R,3S)-2-(2,4-difluorophenyl)-3-methyloxiranyl]methyl]-1H-1,2,4-triazole to a coupling reaction with 4-methylenepiperidine or an organic chemically acceptable salt thereof in the presence of a base and an ionic liquid compound. The base makes the 4-methylenepiperidine or organic chemically acceptable salt thereof anionic. The use of the ionic liquid in the method of the present invention prevents the formation of related substances, shortens the reaction time, and enables easy preparation of the final compound efinaconazole in high purity and yield on a large scale, compared to the use of organic solvents in conventional methods.

Abstract: There is provided a bioactive polyethylene copolymer with a poly(norbornene) backbone comprising one or more repeating units represented by general formula (I) and one or more repeating units represented by general formula (II). Also provided are a polyethylene macromolecule, a material comprising said bioactive polyethylene copolymer, a method of preparing said bioactive polyethylene copolymer and a method of preparing said polyethylene macromolecule.

Abstract: There is provided a bioactive synthetic copolymer with a poly(norbornene) backbone comprising one or more repeating units represented by general formula (I) and one or more repeating units represented by general formula (II). Also provided are a bioactive macromolecule, a material comprising said bioactive synthetic copolymer, a method of preparing said bioactive synthetic copolymer and a method of preparing said bioactive macromolecule.

Abstract: A display device according to an embodiment of the present disclosure can include a display panel configured to display an image, a polarizing plate over the display panel, a front member over the polarizing plate, and a protection member over the front member. The protection member can include at least two protection films and an adhesive layer disposed between the at least two protection films.

Abstract: Proposed is a novel method for preparing liraglutide by means of an ionic liquid and a eutectic solvent, which are environment-friendly solvents. More specifically, the method is characterized in that fractionated peptide 1 represented by the following formula (1) and fractionated peptide 2 represented by the following formula (2) are subjected to a coupling reaction in the presence of an ionic liquid or a eutectic solvent. In preparing GLP-1 analogues such as liraglutide, the present method increases reactivity when producing liraglutide, which is an unprocessed reactant, by using an ionic liquid and a eutectic solvent as environment-friendly solvents instead of using organic solvents. Accordingly, through a relatively short and simple purification process, the present method has advantages of reducing the formation of related substances, improving purity, improving yields, shortening reaction times, reducing production cost, and lowering the manufacturing cost.

Abstract: There is provided a method of preparing silica nanocapsules, the method comprising mixing a surfactant with water at a temperature that is above the gel-to-liquid transition temperature of the surfactant to form a mixture, passing the mixture one or more times through at least one pore to obtain a dispersion of vesicles, and adding a silica precursor to the dispersion of vesicles to form silica nanocapsules. Also provided is a silica nanocapsule formed from a vesicle template, and a method of delivering one or more types of molecules to a subject. In a specific embodiment, hollow silica nanocapsules having substantially lens-shaped are synthesized by employing dimethyldioctadecylammonium bromide (DODAB) or dioctadecyldimethyl ammonium chloride (DODAC) as the vesicle template and tetraethyl orthosilicate (TEOS) as the silica precursor.

Abstract: A solid dispersion of amorphous efinaconazole and a method for preparing the same are proposed. The solid dispersion includes an amorphous form of efinaconazole and at least one stabilization carrier selected from hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), ethyl cellulose (EC), hydroxypropyl methylcellulose acetate succinate (HPMC-AS), polyvinylpyrrolidone (PVP), polyacrylic acid (PAA), saccharin, and malonic acid. The solid dispersion undergoes minimal thermodynamic deformation when exposed to ambient temperature and humidity, achieving improved stability, while maintaining the inherent improved stability and bioavailability of amorphous efinaconazole.

Abstract: The present invention relates to a co-crystalline form of efinaconazole and a pharmaceutically acceptable coformer forming a co-crystalline phase. The present invention also relates to a method for preparing the co-crystalline form. The co-crystallization product of efinaconazole according to the present invention meets all requirements for use as an active ingredient of a pharmaceutical composition and is highly stable to heat and other one or more other ingredients of the composition. Therefore, the co-crystallization product of efinaconazole is suitable for use in the preparation of pharmaceuticals. In addition, the method of the present invention enables the preparation of the co-crystallization product of efinaconazole in a simple and easy manner on a commercial scale.

Abstract: The present invention relates to a novel method for preparing efinaconazole using an ionic liquid as a medium. The method includes subjecting 1-[[(2R,3S)-2-(2,4-difluorophenyl)-3-methyloxiranyl]methyl]-1H-1,2,4-triazole to a coupling reaction with 4-methylenepiperidine or an organic chemically acceptable salt thereof in the presence of a base and an ionic liquid compound. The base makes the 4-methylenepiperidine or organic chemically acceptable salt thereof anionic. The use of the ionic liquid in the method of the present invention prevents the formation of related substances, shortens the reaction time, and enables easy preparation of the final compound efinaconazole in high purity and yield on a large scale, compared to the use of organic solvents in conventional methods.

Abstract: There is provided a method of preparing silica nanocapsules, the method comprising mixing a surfactant with water at a temperature that is above the gel-to-liquid transition temperature of the surfactant to form a mixture, passing the mixture one or more times through at least one pore to obtain a dispersion of vesicles, and adding a silica precursor to the dispersion of vesicles to form silica nanocapsules. Also provided is a silica nanocapsule formed from a vesicle template, and a method of delivering one or more types of molecules to a subject. In a specific embodiment, hollow silica nanocapsules having substantially lens-shaped are synthesized by employing dimethyldioctadecylammonium bromide (DODAB) or dioctadecyldimethyl ammonium chloride (DODAC) as the vesicle template and tetraethyl orthosilicate (TEOS) as the silica precursor.

Abstract: The present invention relates to a method of preparing a polyphenylene sulfide and a high-viscosity polyphenylene sulfide prepared using the method. In this method, the ratio of an organic phase to an aqueous phase is controlled by controlling dehydration conditions, so that high viscosity may be realized without adversely affecting a reaction or physical properties during preparation of the polyphenylene sulfide.

Abstract: The present invention relates to a method of preparing a polyphenylene sulfide and a high-viscosity polyphenylene sulfide prepared using the method. In this method, the ratio of an organic phase to an aqueous phase is controlled by controlling dehydration conditions, so that high viscosity may be realized without adversely affecting a reaction or physical properties during preparation of the polyphenylene sulfide.

Abstract: There is further provided a transparent adhesive composition including a silicon acrylate monomer; a silanol compound; an alkoxy silane compound; and an optical initiator.

Abstract: Disclosed are a single-source precursor for synthesizing metal chalcogenide nanoparticles for producing a light absorption layer of solar cells comprising a Group VI element linked as a ligand to any one metal selected from the group consisting of copper (Cu), zinc (Zn) and tin (Sn), metal chalcogenide nanoparticles produced by heat-treating at least one type of the single-source precursor, a method of preparing the same, a thin film produced using the same and a method of producing the thin film.

Abstract: Disclosed are a single-source precursor for synthesizing metal chalcogenide nanoparticles for producing a light absorption layer of solar cells comprising a Group VI element linked as a ligand to any one metal selected from the group consisting of copper (Cu), zinc (Zn) and tin (Sn), metal chalcogenide nanoparticles produced by heat-treating at least one type of the single-source precursor, a method of preparing the same, a thin film produced using the same and a method of producing the thin film.

Abstract: Disclosed are a single-source precursor for synthesizing metal chalcogenide nanoparticles for producing a light absorption layer of solar cells comprising a Group VI element linked as a ligand to any one metal selected from the group consisting of copper (Cu), zinc (Zn) and tin (Sn), metal chalcogenide nanoparticles produced by heat-treating at least one type of the single-source precursor, a method of preparing the same, a thin film produced using the same and a method of producing the thin film.